Transversus abdominis plane block with liposomal bupivacaine and its effect on opiate use after weight loss surgery: a randomized controlled trial

Transversus Abdominis Plane Block With Liposomal Bupivacaine vs. Regular Anesthetics for Pain Control After Surgery: A Systematic Review and Meta-Analysis

“…Results reported by the included studies for total analgesic consumption are presented in Table 3. Except for the studies of Wong et al (31) and Ha et al (32), which did not report any statistically significant difference in total analgesic consumption between the two groups, all studies reported significantly lower consumption of analgesics in the LB group at some time interval. Except for the study of Guerra et al (35), all studies included pain scores as one of their outcomes.…”

“…For the first primary outcome of our study i.e., total analgesic consumption, a meta-analysis could not be performed owing to significant differences in data collection and presentation among the included studies. Examining the results by specific periods, out of three studies (30,31,36) evaluating analgesic consumption for 0-48 h, only Nedeljkovic et al (30) reported statistically significant results. Hutchins et al (33,34) in their two trials reported analgesic consumption for 24-48 and 48-72 h but with opposite results.…”

“…Ten were excluded as per the reasons mentioned in Table 1 (20)(21)(22)(23)(24)(25)(26)(27)(28)(29). A total of seven studies were included in this systematic review and meta-analysis (30)(31)(32)(33)(34)(35)(36). Details of the included studies are presented in Table 2.…”

“…All studies were conducted in the United States. Five studies were RCTs (30)(31)(32)(33)(34), one was a prospective (35), while another was a retrospective study of a prospectively collected database (36). Ultrasound (US) guidance was used for the TAP blocks in four studies (30,33,34,36).…”

Osmotically Balanced, Large Unilamellar Liposomes for Sustained Bupivacaine Release: From the Development of Liposomes to Their in Vivo Application

“…Furthermore, highdose local anesthetics sometimes cause cardiovascular and central nervous system toxicity when their concentrations are maintained in the body. 16 One of liposomal bupivacaine formulation, namely EXPAREL, wherein bupivacaine is encapsulated in multivesicular liposomes for sustained release, was approved for use as an injection in surgery in 2011 and proposed to provide extended postoperative analgesia, up to 72 h. 17 Several studies have evidenced the e cacy and safety of liposomal bupivacaine for wound in ltration 18,19 and as eld 20,21 and nerve blocks. 22 However, controversies exist regarding its analgesic e cacy.…”